AzTrials
AzTrials

Periodontal DiseasesNCT06465095

Evaluation of Inflammasome Gene Polymorphisms in Periodontitis Patients

An observational study of Periodontal Diseases and Periodontitis, run by Marmara University at 1 site in Turkey (Türkiye).

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The present study aimed to evaluate the distribution of NLRP3, AIM2, and IFI16 inflammasome gene polymorphisms in individuals with Stage III Grade B and C periodontitis and periodontally healthy individuals. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Periodontal Diseases, Periodontitis
What is being tested?
Baseline
How many people
240 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jul 2024to 14 Apr 2025
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Sistemically healthy, non-smokers. Periorodontally healthy, stage III perodontitis B and C periodontitis patients.

Who may be able to join

  • systematically healthy, non-smoker individuals
  • patients between the ages of 18 and 65
  • individuals with periodontally healthy, stage III grade B and C periodontitis diagnoses

Who cannot join

  • having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis...
  • Usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months.
  • Periodontal treatment within the preceding 6 months.
  • Pregnant/ lactating/ postmenopausal females.
  • Current orthodontic treatment.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site, 1 recruiting
  • Marmara University

    Istanbul, Maltepe, 34854

    Hafize Öztürk Özener, 3765376, hafize.ozturk@marmara.edu.tr

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Evaluation of Inflammasome Gene Polymorphisms in Patients With Stage III, Grade B and C Periodontitis

The present study aimed to evaluate the distribution of NLRP3, AIM2, and IFI16 inflammasome gene polymorphisms in individuals with Stage III Grade B and C periodontitis and periodontally healthy individuals. 80 periodontally healthy, 80 Stage III Grade B and 80 Stage III Grade C periodontitis patients will be enrolled. Blood samples will be collected from each participants and clinical parameteres will be recorded for whole mouth. DNA isolation will be performed from all samples. The SNP regions with the numbers rs4612666, rs75985579, and rs2793845 will be detected from DNA material using Real-Time PCR device genotyping kits. Data will be analyzed using statistical tests.

Read the detailed description

Innate immune response is the first line of defense mechanism of the body against pathogens. One of the most important proteins involved in the innate immune response are the inflammasomes which are multimeric protein complexes composed of a sensor molecule (the PRR), typically the adapter molecule apoptosis-associated speck-like protein containing a caspase-recruitment domain (CARD), and the protease caspase-1. Different types of inflammasomes have been described. In periodontal disease, inflammasome activation is associated with the release of pro-inflammatory cytokines, which can lead to tissue destruction and periodontal damage.

Progression rate, onset age, and severity of periodontal disease are influenced by some modifiable or non-modifiable risk factors present in the host. Genetic polymorphisms are non-modifiable risk factors for periodontitis. Variations in inflammasome genes may be determinants in the development of periodontal disease by leading to diversity in inflammatory markers.

Sample size is determined based on a previous study which analyzes the effect of NLRP3 gene polymorphism on periodontitis susceptibility. For rs4612666 group, with an α value of 0.05 and a power of 80%, it is determined that there should be 80 participants in each group. Totally 240 patients are included (80 periodontally healthy, 80 Stage III Grade B periodontitis, 80 Stage III Grade C periodontitis). The whole mouth clinical periodontal examination includes measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. Periodontal diagnosis of each patient has been made according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Healthy group includes individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP < 10%, probing depth ≤ 3 mm. Stage III Grade B periodontitis patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 and Stage III Grade C patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is >1.

Sample Collection and DNA Isolation and Genotyping A total of 5 mL of blood is collected from the antecubital fossa by venepuncture method from each participants and stored at -80°C until analysis day. DNA isolation has been made using genomic DNA kits. rs4612666, rs75985579, and rs2793845 SNP regions are detected from DNA material using Real-Time PCR device genotyping kits.

Statistical analysis has been performed with standard statistical software package by selecting appropriate tests.

Being tested
Baseline
Keywords
Periodontitis, gene, polymorphism
Medical subject headings
Periodontal Diseases, Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BaselineGenetic

    Measurements and sampling

Study groups in NCT06465095
Study groupRoleWhat they receive
HealthyIndividuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP < 10%, probing depth ≤ 3 mm.
Receives: Genetic: Baseline
Stage III Grade B PeriodontitisIndividuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 will be included.
Receives: Genetic: Baseline
Stage III Grade C PeriodontitisIndividuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is >1 will be included.
Receives: Genetic: Baseline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. NLRP3 gene polymorphism

    SNP

    Measured: Baseline

Secondary outcomes (2)
  1. AIM2 gene polymorphism

    SNP

    Measured: Baseline

  2. IFI16

    SNP

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2024
  2. Study start1 Jul 2024
  3. Primary completion14 Apr 2025 (estimated)
  4. Study completion14 Apr 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
240 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT06465095
Sponsor's protocol ID
09-2023-1700
Status last verified
Feb 2024
First submitted
13 Jun 2024
Last updated
16 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Saka N, Yilmaz OO, Tacal Aslan B, Ozturk Ozener H. The role of NLRP3, AIM2, and IFI16 gene polymorphisms in periodontitis susceptibility: a case control study. BMC Oral Health. 2026 Feb 3;26(1):432. doi: 10.1186/s12903-026-07740-w.

    PubMed 41634660

Questions about this trial

What is this clinical trial studying?

An observational study of Periodontal Diseases and Periodontitis, run by Marmara University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 16 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

NLRP3 gene polymorphism (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06465095, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in